Company profile
Vaxxinity, Inc.
OTC: VAXX · Healthcare · Biotechnology
#1161 of 1,418 Healthcare companies by revenuebottom-decile growth
EA Score
——FH —DQ 34GM —SS 28
v0.1 · 25/100 weight · pillars only
↑ filing timeliness, workforce scale · ↓ revenue growth (YoY), Piotroski F
Methodology →Revenue TTM
$0
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
-$56.9M
Employees
57
as of 2026-08-25
Market cap
$12.7k
as of 2026-08-25
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$0$02022
Net income-$56.9M-$56.9M2023
Operating income-$58.3M-$58.3M2023
Total assets$44.3M$44.3M2023
Liabilities$30.9M$30.9M2023
Equity$13.4M$13.4M2023
Revenue trend
FY2021 – FY2022 · USD
FY21
FY21
FY22
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Vaxxinity, Inc.’s revenue?
Vaxxinity, Inc. booked $0 in FY2022 revenue, contracting 100% year over year — among the slowest-growing Healthcare companies we track, at a -Infinity% net margin.
Peers · Healthcare
VioQuest Pharmaceuticals, Inc.——Golden Developing Solutions, Inc.——CNBX Pharmaceuticals Inc.19DNovAccess Global Inc.——VIA Pharmaceuticals, Inc.——OneLife Technologies Corp.——Neighbors
Dallas →Key facts
CEOMei Mei Hu
SectorHealthcare
IndustryBiotechnology
HeadquartersDallas, TX
ExchangeOTC: VAXX
Employees57
IPO date2021-11-11
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.